Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration
- PMID: 2022223
- DOI: 10.1159/000473608
Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration
Abstract
Neutrophil-activating peptide-1/interleukin-8 (NAP-1/IL-8), secreted by monocytes, macrophages and a number of other cells, acts as a chemoattractant for neutrophil leukocytes and stimulates them to produce a series of responses such as shape change, adherence, exocytosis and respiratory burst, events that are of importance in inflammation. To study the release of NAP-1/IL-8, two human models of inflammation were chosen: transurethral resection of superficial bladder cancer and the subsequent instillation of bacillus Calmette-Guérin (BCG), performed in order to reduce the recurrence rate of papillary bladder tumors. As the secretions of the bladder wall are retained in the urine, patients' urine was collected during 4-hour periods. These urine samples were chromatographed on phosphocellulose. In the elution fractions NAP-1/IL-8 was quantified by a bioassay that measured the elastase release by human neutrophils. The neutrophil-stimulating activity was further purified by reverse phase high performance liquid chromatography. Although no NAP-1/IL-8 activity could be detected in normal individuals, formation of this inflammatory cytokine was observed in patients after transurethral resection and after BCG treatment. The significance and possible use of this secretion are discussed.
Similar articles
-
Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.J Urol. 2000 Dec;164(6):2129-33. J Urol. 2000. PMID: 11061941
-
Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients.J Urol. 1997 Nov;158(5):1728-31; discussion 1731-2. doi: 10.1016/s0022-5347(01)64111-9. J Urol. 1997. PMID: 9334588 Clinical Trial.
-
A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.J Urol. 1996 Sep;156(3):962-6. doi: 10.1016/s0022-5347(01)65673-8. J Urol. 1996. PMID: 8709374 Clinical Trial.
-
Intravesical bacillus Calmette-Guérin (BCG) in superficial bladder tumors. An overview.Arch Esp Urol. 1990;43 Suppl 2:133-8. Arch Esp Urol. 1990. PMID: 2096774 Review. No abstract available.
-
Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.J Urol. 2017 May;197(5):1189-1199. doi: 10.1016/j.juro.2016.12.090. Epub 2016 Dec 24. J Urol. 2017. PMID: 28027868
Cited by
-
Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.Urol Res. 1994;22(3):177-84. doi: 10.1007/BF00571847. Urol Res. 1994. PMID: 7992464
-
Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guérin immunotherapy.Cancer Immunol Immunother. 1995 Feb;40(2):119-24. doi: 10.1007/BF01520294. Cancer Immunol Immunother. 1995. PMID: 7882382 Free PMC article.
-
Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer.Urol Res. 1997;25(1):31-4. doi: 10.1007/BF00941903. Urol Res. 1997. PMID: 9079743
-
Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.Clin Exp Immunol. 1995 Mar;99(3):369-75. doi: 10.1111/j.1365-2249.1995.tb05560.x. Clin Exp Immunol. 1995. PMID: 7882559 Free PMC article.
-
Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder.Cancer Immunol Immunother. 2003 Aug;52(8):481-6. doi: 10.1007/s00262-003-0384-9. Epub 2003 Apr 18. Cancer Immunol Immunother. 2003. PMID: 12707736 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials